As the article mentions, the pricing of this will be extremely interesting. The outright Hep C cure (Sofosbuvir/Sovaldi) was one of the big stories in pharmacoe

As the article mentions, the pricing of this will be extremely interesting. The outright Hep C cure (Sofosbuvir/Sovaldi) was one of the big stories in pharmacoeconomics last year, which is very interestingly priced globally (Nice paywalled article discussing this - http://thelancet.com/journals/langlo/article/PIIS2214-109X(15)00156-4/fulltext http://thelancet.com/journals/langlo/article/PIIS2214-109X(1...)